Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30893
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDenton, Christopher P-
dc.contributor.authorGoh, Nicole S L-
dc.contributor.authorHumphries, Stephen M-
dc.contributor.authorMaher, Toby M-
dc.contributor.authorSpiera, Robert-
dc.contributor.authorDevaraj, Anand-
dc.contributor.authorHo, Lawrence-
dc.contributor.authorStock, Christian-
dc.contributor.authorErhardt, Elvira-
dc.contributor.authorAlves, Margarida-
dc.contributor.authorWells, Athol U-
dc.date2022-
dc.date.accessioned2022-09-20T06:51:49Z-
dc.date.available2022-09-20T06:51:49Z-
dc.date.issued2023-05-
dc.identifier.citationRheumatology (Oxford, England) 2023-05-02; 62(5)en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30893-
dc.description.abstractTo assess associations between the extent of fibrotic interstitial lung disease (ILD) and forced vital capacity (FVC) at baseline and change in FVC over 52 weeks in patients with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial. We used generalised additive models, which involve few assumptions and allow for interaction between non-linear effects, to assess associations between the extent of fibrotic ILD on high-resolution computed tomography (HRCT), and the interplay of extent of fibrotic ILD on HRCT and FVC % predicted, at baseline and FVC decline over 52 weeks. In the placebo group (n = 288), there was weak evidence of a modest association between a greater extent of fibrotic ILD at baseline and a greater decline in FVC % predicted at week 52 (r: -0.09 [95% CI -0.2, 0.03]). Higher values of both the extent of fibrotic ILD and FVC % predicted at baseline tended to be associated with greater decline in FVC % predicted at week 52. In the nintedanib group (n = 288), there was no evidence of an association between the extent of fibrotic ILD at baseline and decline in FVC % predicted at week 52 (r: 0.01 [95% CI: -0.11, 0.12]) or between the interplay of extent of fibrotic ILD and FVC % predicted at baseline and decline in FVC % predicted at week 52. Data from the SENSCIS trial suggest that patients with SSc-ILD are at risk of ILD progression and benefit from nintedanib largely irrespective of their extent of fibrotic ILD at baseline. ClinicalTrials.gov, https://clinicaltrials.gov, NCT02597933.en_US
dc.language.isoeng-
dc.subjectautoimmune diseasesen_US
dc.subjectpulmonary fibrosisen_US
dc.subjectvital capacityen_US
dc.titleExtent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleRheumatology (Oxford, England)en_US
dc.identifier.affiliationCenter for Interstitial Lung Diseases, University of Washington, Seattle, Washington, USAen_US
dc.identifier.affiliationDepartment of Radiology, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, London, UKen_US
dc.identifier.affiliationNational Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, UKen_US
dc.identifier.affiliationDepartment of Radiology, National Jewish Health, Denver, Colorado, USAen_US
dc.identifier.affiliationNational Heart and Lung Institute, Imperial College London, London, UK, and Keck School of Medicine, University of Southern California, Los Angeles, California, USAen_US
dc.identifier.affiliationDivision of Rheumatology, Hospital for Special Surgery, New York, New York, USAen_US
dc.identifier.affiliationRespiratory and Sleep Medicineen_US
dc.identifier.affiliationCentre for Rheumatology and Connective Tissue Diseases, University College London Division of Medicine, London, UKen_US
dc.identifier.affiliationBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein.en_US
dc.identifier.affiliationmainanalytics GmbH, Sulzbach, Germany.en_US
dc.identifier.affiliationBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.en_US
dc.identifier.affiliationInstitute for Breathing and Sleepen_US
dc.identifier.doi10.1093/rheumatology/keac535en_US
dc.type.contentTexten_US
dc.identifier.pubmedid36111858-
local.name.researcherGoh, Nicole S L
item.languageiso639-1en-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptRespiratory and Sleep Medicine-
crisitem.author.deptInstitute for Breathing and Sleep-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

56
checked on Nov 7, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.